Structured Review

Promega adra1b myc
(A) Co-immunoprecipitation (Co-IP) of <t>ADRA1B-Myc</t> and GPR143-HA. Bands were detected by anti-Myc (left) or by anti-HA (right) antibodies. (B) Protein levels of pERK and whole ERK 10 minutes after the treatment with phenylephrine. (C) Summarized data of pERK/ERK (% of control) in HEK293 cells coexpressing ADRA1B-Myc and free-EGFP or ADRA1B-Myc and GPR143-EGFP (F1,32 = 7.899, P < 0.001, n = 5). (D) Interaction between ADRA1B-Myc and GPR143-HA in the presence or absence of L-DOPA. Note that the interaction was enhanced in the presence of L-DOPA for 1 minute. The arrowhead indicates predicted ADRA1B. (E) TIRF microscopic images of GPR143-EGFP (left), ADRA1B-mCherry (center), and merged images (right) as indicated by white arrowheads (n = 3, independent experiments). Scale bar: 3.5 μm. (F) FRET efficiency between Venus and CFP at the plasma membrane. *P < 0.05, **P < 0.01, 1-way ANOVA with Bonferroni’s multiple comparisons test (n = 36–59). n.s., not significant. (G) Displacement binding curve of [H3]-prazosin (0.4 nM) by phenylephrine in HEK293 cells expressing ADRA1B-Myc and GPR143-EGFP or ADRA1B-Myc and free-EGFP (F1,40 = 19.31, ***P < 0.001, n = 3). Two-way ANOVA with Bonferroni’s multiple comparisons test.
Adra1b Myc, supplied by Promega, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/adra1b myc/product/Promega
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
adra1b myc - by Bioz Stars, 2023-02
86/100 stars

Images

1) Product Images from "L-DOPA sensitizes vasomotor tone by modulating the vascular alpha1-adrenergic receptor"

Article Title: L-DOPA sensitizes vasomotor tone by modulating the vascular alpha1-adrenergic receptor

Journal: JCI Insight

doi: 10.1172/jci.insight.90903

(A) Co-immunoprecipitation (Co-IP) of ADRA1B-Myc and GPR143-HA. Bands were detected by anti-Myc (left) or by anti-HA (right) antibodies. (B) Protein levels of pERK and whole ERK 10 minutes after the treatment with phenylephrine. (C) Summarized data of pERK/ERK (% of control) in HEK293 cells coexpressing ADRA1B-Myc and free-EGFP or ADRA1B-Myc and GPR143-EGFP (F1,32 = 7.899, P < 0.001, n = 5). (D) Interaction between ADRA1B-Myc and GPR143-HA in the presence or absence of L-DOPA. Note that the interaction was enhanced in the presence of L-DOPA for 1 minute. The arrowhead indicates predicted ADRA1B. (E) TIRF microscopic images of GPR143-EGFP (left), ADRA1B-mCherry (center), and merged images (right) as indicated by white arrowheads (n = 3, independent experiments). Scale bar: 3.5 μm. (F) FRET efficiency between Venus and CFP at the plasma membrane. *P < 0.05, **P < 0.01, 1-way ANOVA with Bonferroni’s multiple comparisons test (n = 36–59). n.s., not significant. (G) Displacement binding curve of [H3]-prazosin (0.4 nM) by phenylephrine in HEK293 cells expressing ADRA1B-Myc and GPR143-EGFP or ADRA1B-Myc and free-EGFP (F1,40 = 19.31, ***P < 0.001, n = 3). Two-way ANOVA with Bonferroni’s multiple comparisons test.
Figure Legend Snippet: (A) Co-immunoprecipitation (Co-IP) of ADRA1B-Myc and GPR143-HA. Bands were detected by anti-Myc (left) or by anti-HA (right) antibodies. (B) Protein levels of pERK and whole ERK 10 minutes after the treatment with phenylephrine. (C) Summarized data of pERK/ERK (% of control) in HEK293 cells coexpressing ADRA1B-Myc and free-EGFP or ADRA1B-Myc and GPR143-EGFP (F1,32 = 7.899, P < 0.001, n = 5). (D) Interaction between ADRA1B-Myc and GPR143-HA in the presence or absence of L-DOPA. Note that the interaction was enhanced in the presence of L-DOPA for 1 minute. The arrowhead indicates predicted ADRA1B. (E) TIRF microscopic images of GPR143-EGFP (left), ADRA1B-mCherry (center), and merged images (right) as indicated by white arrowheads (n = 3, independent experiments). Scale bar: 3.5 μm. (F) FRET efficiency between Venus and CFP at the plasma membrane. *P < 0.05, **P < 0.01, 1-way ANOVA with Bonferroni’s multiple comparisons test (n = 36–59). n.s., not significant. (G) Displacement binding curve of [H3]-prazosin (0.4 nM) by phenylephrine in HEK293 cells expressing ADRA1B-Myc and GPR143-EGFP or ADRA1B-Myc and free-EGFP (F1,40 = 19.31, ***P < 0.001, n = 3). Two-way ANOVA with Bonferroni’s multiple comparisons test.

Techniques Used: Immunoprecipitation, Co-Immunoprecipitation Assay, Binding Assay, Expressing

Expression of GPR143 (A) and ADRA1B (C) in the liver (arrowheads). No GPR143 signals were observed in the liver of Gpr143–/y mice (B). No ADRA1B signals were observed in sections incubated with the antigenic peptide–preadsorbed antibody (D). Scale bar: 100 μm. Endogenous interaction between GPR143 and ADRA1B. (E) The GPR143-ADRA1B interacting signals (green) were detected by in situ proximity ligation assay technology in WT liver (arrowheads). (F) No interacting signals were observed in Gpr143–/y liver (n = 2, independent experiments). The nucleus was counterstained by DAPI (blue). Scale bars: 5 μm.
Figure Legend Snippet: Expression of GPR143 (A) and ADRA1B (C) in the liver (arrowheads). No GPR143 signals were observed in the liver of Gpr143–/y mice (B). No ADRA1B signals were observed in sections incubated with the antigenic peptide–preadsorbed antibody (D). Scale bar: 100 μm. Endogenous interaction between GPR143 and ADRA1B. (E) The GPR143-ADRA1B interacting signals (green) were detected by in situ proximity ligation assay technology in WT liver (arrowheads). (F) No interacting signals were observed in Gpr143–/y liver (n = 2, independent experiments). The nucleus was counterstained by DAPI (blue). Scale bars: 5 μm.

Techniques Used: Expressing, Incubation, In Situ, Proximity Ligation Assay


Structured Review

Promega adra1b myc
(A) Co-immunoprecipitation (Co-IP) of <t>ADRA1B-Myc</t> and GPR143-HA. Bands were detected by anti-Myc (left) or by anti-HA (right) antibodies. (B) Protein levels of pERK and whole ERK 10 minutes after the treatment with phenylephrine. (C) Summarized data of pERK/ERK (% of control) in HEK293 cells coexpressing ADRA1B-Myc and free-EGFP or ADRA1B-Myc and GPR143-EGFP (F1,32 = 7.899, P < 0.001, n = 5). (D) Interaction between ADRA1B-Myc and GPR143-HA in the presence or absence of L-DOPA. Note that the interaction was enhanced in the presence of L-DOPA for 1 minute. The arrowhead indicates predicted ADRA1B. (E) TIRF microscopic images of GPR143-EGFP (left), ADRA1B-mCherry (center), and merged images (right) as indicated by white arrowheads (n = 3, independent experiments). Scale bar: 3.5 μm. (F) FRET efficiency between Venus and CFP at the plasma membrane. *P < 0.05, **P < 0.01, 1-way ANOVA with Bonferroni’s multiple comparisons test (n = 36–59). n.s., not significant. (G) Displacement binding curve of [H3]-prazosin (0.4 nM) by phenylephrine in HEK293 cells expressing ADRA1B-Myc and GPR143-EGFP or ADRA1B-Myc and free-EGFP (F1,40 = 19.31, ***P < 0.001, n = 3). Two-way ANOVA with Bonferroni’s multiple comparisons test.
Adra1b Myc, supplied by Promega, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/adra1b myc/product/Promega
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
adra1b myc - by Bioz Stars, 2023-02
86/100 stars

Images

1) Product Images from "L-DOPA sensitizes vasomotor tone by modulating the vascular alpha1-adrenergic receptor"

Article Title: L-DOPA sensitizes vasomotor tone by modulating the vascular alpha1-adrenergic receptor

Journal: JCI Insight

doi: 10.1172/jci.insight.90903

(A) Co-immunoprecipitation (Co-IP) of ADRA1B-Myc and GPR143-HA. Bands were detected by anti-Myc (left) or by anti-HA (right) antibodies. (B) Protein levels of pERK and whole ERK 10 minutes after the treatment with phenylephrine. (C) Summarized data of pERK/ERK (% of control) in HEK293 cells coexpressing ADRA1B-Myc and free-EGFP or ADRA1B-Myc and GPR143-EGFP (F1,32 = 7.899, P < 0.001, n = 5). (D) Interaction between ADRA1B-Myc and GPR143-HA in the presence or absence of L-DOPA. Note that the interaction was enhanced in the presence of L-DOPA for 1 minute. The arrowhead indicates predicted ADRA1B. (E) TIRF microscopic images of GPR143-EGFP (left), ADRA1B-mCherry (center), and merged images (right) as indicated by white arrowheads (n = 3, independent experiments). Scale bar: 3.5 μm. (F) FRET efficiency between Venus and CFP at the plasma membrane. *P < 0.05, **P < 0.01, 1-way ANOVA with Bonferroni’s multiple comparisons test (n = 36–59). n.s., not significant. (G) Displacement binding curve of [H3]-prazosin (0.4 nM) by phenylephrine in HEK293 cells expressing ADRA1B-Myc and GPR143-EGFP or ADRA1B-Myc and free-EGFP (F1,40 = 19.31, ***P < 0.001, n = 3). Two-way ANOVA with Bonferroni’s multiple comparisons test.
Figure Legend Snippet: (A) Co-immunoprecipitation (Co-IP) of ADRA1B-Myc and GPR143-HA. Bands were detected by anti-Myc (left) or by anti-HA (right) antibodies. (B) Protein levels of pERK and whole ERK 10 minutes after the treatment with phenylephrine. (C) Summarized data of pERK/ERK (% of control) in HEK293 cells coexpressing ADRA1B-Myc and free-EGFP or ADRA1B-Myc and GPR143-EGFP (F1,32 = 7.899, P < 0.001, n = 5). (D) Interaction between ADRA1B-Myc and GPR143-HA in the presence or absence of L-DOPA. Note that the interaction was enhanced in the presence of L-DOPA for 1 minute. The arrowhead indicates predicted ADRA1B. (E) TIRF microscopic images of GPR143-EGFP (left), ADRA1B-mCherry (center), and merged images (right) as indicated by white arrowheads (n = 3, independent experiments). Scale bar: 3.5 μm. (F) FRET efficiency between Venus and CFP at the plasma membrane. *P < 0.05, **P < 0.01, 1-way ANOVA with Bonferroni’s multiple comparisons test (n = 36–59). n.s., not significant. (G) Displacement binding curve of [H3]-prazosin (0.4 nM) by phenylephrine in HEK293 cells expressing ADRA1B-Myc and GPR143-EGFP or ADRA1B-Myc and free-EGFP (F1,40 = 19.31, ***P < 0.001, n = 3). Two-way ANOVA with Bonferroni’s multiple comparisons test.

Techniques Used: Immunoprecipitation, Co-Immunoprecipitation Assay, Binding Assay, Expressing

Expression of GPR143 (A) and ADRA1B (C) in the liver (arrowheads). No GPR143 signals were observed in the liver of Gpr143–/y mice (B). No ADRA1B signals were observed in sections incubated with the antigenic peptide–preadsorbed antibody (D). Scale bar: 100 μm. Endogenous interaction between GPR143 and ADRA1B. (E) The GPR143-ADRA1B interacting signals (green) were detected by in situ proximity ligation assay technology in WT liver (arrowheads). (F) No interacting signals were observed in Gpr143–/y liver (n = 2, independent experiments). The nucleus was counterstained by DAPI (blue). Scale bars: 5 μm.
Figure Legend Snippet: Expression of GPR143 (A) and ADRA1B (C) in the liver (arrowheads). No GPR143 signals were observed in the liver of Gpr143–/y mice (B). No ADRA1B signals were observed in sections incubated with the antigenic peptide–preadsorbed antibody (D). Scale bar: 100 μm. Endogenous interaction between GPR143 and ADRA1B. (E) The GPR143-ADRA1B interacting signals (green) were detected by in situ proximity ligation assay technology in WT liver (arrowheads). (F) No interacting signals were observed in Gpr143–/y liver (n = 2, independent experiments). The nucleus was counterstained by DAPI (blue). Scale bars: 5 μm.

Techniques Used: Expressing, Incubation, In Situ, Proximity Ligation Assay